RT Journal Article
SR Electronic
T1 Design and user experience testing of a polygenic score report: a qualitative study of prospective users
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.14.21255397
DO 10.1101/2021.04.14.21255397
A1 Brockman, Deanna G.
A1 Petronio, Lia
A1 Dron, Jacqueline S.
A1 Kwon, Bum Chul
A1 Vosburg, Trish
A1 Nip, Lisa
A1 Tang, Andrew
A1 O’Reilly, Mary
A1 Lennon, Niall
A1 Wong, Bang
A1 Ng, Kenney
A1 Huang, Katherine H.
A1 Fahed, Akl C.
A1 Khera, Amit V.
YR 2021
UL http://medrxiv.org/content/early/2021/04/20/2021.04.14.21255397.abstract
AB Background Polygenic scores – which quantify inherited risk by integrating information from many common sites of DNA variation – may enable a tailored approach to clinical medicine. However, alongside considerable enthusiasm, we and others have highlighted a lack of systematic approaches for score disclosure. Here, we review the landscape of polygenic score reporting and describe a generalizable approach for development of polygenic score disclosure tools for coronary artery disease.Methods First, we assembled a working group of clinicians, geneticists, data visualization specialists, and software developers. The group reviewed existing polygenic score reports and then designed a two-page mock polygenic score report for coronary artery disease. We then conducted a qualitative user-experience study with this report and an interview guide focused on comprehension, experience, and attitudes. Interviews were transcribed and thematically analyzed for themes identification.Results We conducted interviews with ten adult individuals (50% females, 70% without prior genetic testing experience, age range 20 to 70 years) recruited via an online platform. We identified three themes from interviews: (1) visual elements, such as color and simple graphics, enable participants to interpret, relate to, and contextualize their polygenic score, (2) word-based descriptions of risk and polygenic scores presented as percentiles were most often recognized and understood, (3) participants had varying levels of interest in understanding complex genomic information and therefore would benefit from additional resources that can adapt to their individual needs in real time. In response to user feedback, colors used for communicating risk were modified to minimize unintended color associations and odds ratios were removed. Of note, all 10 participants expressed interest in receiving this report based on their personal genomic information.Conclusions Our findings describe a generalizable approach to develop and test a polygenic score disclosure tool that is desired by the general public. These results are likely to inform ongoing efforts related to polygenic score disclosure within clinical practice.Competing Interest StatementB.C.K. and K.N. are employees of IBM Research. A.C.F. is a consultant and holds equity in Goodpath. A.V.K. has served as a scientific advisor to Sanofi, Medicines Company, Maze Therapeutics, Navitor Pharmaceuticals, Sarepta Therapeutics, Verve Therapeutics, Amgen, Color, and Columbia University (NIH); received speaking fees from Illumina, MedGenome, Amgen, and the Novartis Institute for Biomedical Research; received sponsored research agreements from the Novartis Institute for Biomedical Research and IBM Research.Funding StatementThis study was funded by a sponsored research agreement from IBM Research, grant 1K08HG010155 (to A.V.K.) from the National Human Genome Research Institute, a Hassenfeld Scholar Award from Massachusetts General Hospital (to A.V.K.), a Merkin Institute Fellowship from the Broad Institute of MIT and Harvard (to A.V.K.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Mass General Brigham Institutional Review Board (2020P003088).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFor additional information about data referred to in the manuscript, contact D. Brockman (Deanna.brockman@mgh.harvard.edu).ACMGAmerican College of Medical Genetics